Pan-RAF

Notes

original target text: Pan-RAF inhibitor

RAF proteins (ARAF, BRAF, and CRAF/RAF1) are kinases that act early in the MAPK (mitogen-activated protein kinase) signaling cascade, a pathway that relays growth signals from cell-surface receptors to the nucleus, driving cell division and survival. In many cancers, mutations in RAS or BRAF genes lock this pathway in an active state, causing uncontrolled proliferation. Selective BRAF inhibitors were developed first, but tumors often escape their effect because the other RAF isoforms, or RAF dimers, sustain signaling even when BRAF is blocked. A pan-RAF inhibitor is designed to suppress all three RAF isoforms simultaneously, including the dimeric complexes that selective agents cannot fully control. This broader inhibition aims to close off escape routes that tumors use to reactivate MAPK signaling, making pan-RAF agents relevant in cancers driven by RAS mutations, atypical BRAF alterations, or acquired resistance to earlier-generation RAF-directed therapies. Because the MAPK pathway is also active in healthy tissue, modulating it carries trade-offs that must be weighed alongside its therapeutic benefit. Understanding RAF biology is central to grasping why drug designers have pursued increasingly comprehensive strategies for blocking this pathway across a spectrum of tumor genetics.